Day Two
Thursday, January 20, 2022
8:00 am Chair’s Opening Remarks
A Deep Dive into DNA Damage Repair for GBM
8:10 am Small molecule epichaperome inhibitors to treat cancers and neurodegenerative disease
Synopsis
- Icapamespib (PU-AD) a small molecule epichaperome inhibitor is being
developed for brain cancers and neurodegenerative diseases - Icapamespib is BBB permeable, inhibits epichaperome activity,
initiates degradation of disease associated proteins, normalizes cellular
pathways and causes cancer cell death or recovery of neuronal functions - In preclinical studies icapamespib decreased tumor growth in human GBM
explant xenografts, initiated degradation of oncoproteins and increased survival
8:30 am Targeting the DNA Damage Response in Glioma: Emerging New Concepts and Novel Directions
Synopsis
- Overview of the DNA damage response (DDR) and how it can be targeted therapeutically for GBM
- Review on promising new DDR inhibitors and DNA damaging agents, which are either in development or in the clinic for GBM
- Discuss emerging DDR targets, key hurdles, and future directions in the GBM space
9:00 am Tumor treating fields (TTFields) in glioblastoma
Synopsis
- Overview of tumor treating fields (TTFields), a form of alternating electric fields therapy in cancer
- Review the effects of TTFields on DNA damage repair (DDR) in glioblastoma
- Discuss the membrane permeabilizing effects of TTFields in glioblastoma and combination strategies with other therapies’
9:30 am Morning Break & Networking
Financing BioPharma for Rapid GBM Drug Development
10:40 am Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Synopsis
- Explore the challenges of funding development
- How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline?
- How can the industry come together to overcome the paucity of funding?
Optimizing Immunotherapies for GBM Drug Development
11:40 am Inovio’s DNA Medicine for the Treatment of Glioblastoma
Synopsis
- Using novel DNA-encoded medicines to treat human cancers such as GBM
- Generating robust, specific anti-tumor T cells against GBM antigens
- Combining DNA medicine with immune checkpoint inhibitors to build
clinical responses
12:10 pm Targeting EGFR in in glioblastoma with a novel brain-penetrant small molecule EGFR-TKI
Synopsis
- A novel EGFR-TKi with extraordinary brain-selective distribution ( >20-fold brain to plasma ratio)
- It has a favorable oral PK and safety profile with a low systemic toxicity
- Superior activity against GBM in preclinical models (patient-derived and GEM models)
12:40 pm Mechanisms of Immunosuppression
Synopsis
- Understand current landscape of immunotherapy for brain tumors
- Understand the current obstacles for developing effective immunotherapies for brain tumors
1:10 pm Lunch & Networking
2:10 pm Presentation Slot Reserved for Istari Oncology
Synopsis
2:40 pm Leveraging the Lysosome to Treat Glioblastoma
Synopsis
- BXQ-350 – a unique, first in class, lysosomal protein (in lipid nanovesicle) involved in cellular homeostasis
- Phase 1 clinical trial findings of extraordinary safety and tolerability with monotherapy effect
- Planned clinical trials in newly diagnosed GBM – combination therapy
with radiation and temozolomide
3:10 pm Optimization of an Oncolytic HSV-1 for the Treatment of Glioblastoma
Synopsis
- Optimization of oHSV backbone 7 Transgenes
- Development of clinical candidate oncolytic virus
3:40 pm Afternoon Break & Refreshments
4:10 pm Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy
Synopsis
- Review the biological profile of treatment-refractory glioblastoma
- Explore the application of an integrative multi-omics target discovery platform for human GBM which incorporates DNA cellular barcoding, glycocapture profiling of the cell surface proteome, RNA sequencing, single-cell sequencing and genome-wide CRISPR screening of primary and recurrent GBM
- Review the rationale for combinatorial polytherapy for targeting intratumoral heterogeneity and therapy-driven clonal evolution found in GBM recurrence
4:40 pm Novel Hydrogel-Based Localized Treatment For Glioblastoma
Synopsis
- Discovery of a novel target for Glioblastoma using a machine learning algorithm
- Development of a tailored hydrogel-based drug delivery system to be used as adjunct to surgery
- Presentation of preclinical in vitro and in vivo data supporting clinical
translation